Details for New Drug Application (NDA): 022350
✉ Email this page to a colleague
NDA 022350 describes ONGLYZA, which is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ONGLYZA profile page.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the saxagliptin hydrochloride profile page.
The generic ingredient in ONGLYZA is saxagliptin hydrochloride. There are fifteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the saxagliptin hydrochloride profile page.
Summary for 022350
| Tradename: | ONGLYZA |
| Applicant: | Astrazeneca Ab |
| Ingredient: | saxagliptin hydrochloride |
| Patents: | 2 |
| Formulation / Manufacturing: | see details |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 022350
Generic Entry Date for 022350*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 022350
| Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Suppliers and Packaging for NDA: 022350
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ONGLYZA | saxagliptin hydrochloride | TABLET;ORAL | 022350 | NDA | AstraZeneca Pharmaceuticals LP | 0310-6100 | 0310-6100-30 | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0310-6100-30) |
| ONGLYZA | saxagliptin hydrochloride | TABLET;ORAL | 022350 | NDA | AstraZeneca Pharmaceuticals LP | 0310-6100 | 0310-6100-90 | 90 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (0310-6100-90) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 2.5MG BASE | ||||
| Approval Date: | Jul 31, 2009 | TE: | RLD: | Yes | |||||
| Patent: | See Plans and Pricing | Patent Expiration: | Nov 30, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | See Plans and Pricing | Patent Expiration: | Jul 31, 2023 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN | ||||||||
| Patent: | See Plans and Pricing | Patent Expiration: | Jul 31, 2023 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA | ||||||||
Expired US Patents for NDA 022350
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Astrazeneca Ab | ONGLYZA | saxagliptin hydrochloride | TABLET;ORAL | 022350-001 | Jul 31, 2009 | See Plans and Pricing | See Plans and Pricing |
| Astrazeneca Ab | ONGLYZA | saxagliptin hydrochloride | TABLET;ORAL | 022350-002 | Jul 31, 2009 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
